The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.

ADULTS can beat peanut allergies by eating tiny amounts with medical help and building up a tolerance, an NHS study suggests.

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Living with Chronic Spontaneous Urticaria can be challenging, especially when triggers seem ubiquitous. Here's what you need ...

Chris Brookes-Smith could have died from eating peanuts - but taking part in a clinical trial has changed his life.

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.